CBD Probably Reduces Seizures in Refractory Epilepsy, But Raises Risk of Serious Adverse Events
Cannabidiol treatment resistant epilepsy shows probable seizure reduction benefits at 10 and 20 mg/kg/day doses. However, cannabidiol treatment resistant epilepsy also raises the risk of serious adverse events. This systematic review highlights the need…
Cannabidiol Probably Reduces Seizures in Drug-Resistant Epilepsy—But Serious Side Effects Also Rise
The cannabidiol pediatric epilepsy dosing 2025 review shows that pharmaceutical-grade cannabidiol probably reduces seizures in treatment-resistant epilepsy. This review highlights a meaningful benefit-risk trade-off with increased serious adverse events…
Cannabidiol for Lennox-Gastaut: Clinical Trial Evidence and Insights
Clinically meaningful cannabidiol reduction in drop seizures offers new hope for Lennox-Gastaut syndrome patients. Recent clinical trial evidence shows that even reductions below 50% can improve patient outcomes. Caregiver reports align with seizure…